Alyeska Investment Group, L.P. Intra Cellular Therapies, Inc. Transaction History
Alyeska Investment Group, L.P.
- $25 Billion
- Q4 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 451,146 shares of ITCI stock, worth $57.9 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
451,146
Previous 931,130
51.55%
Holding current value
$57.9 Million
Previous $68.1 Million
44.66%
% of portfolio
0.15%
Previous 0.38%
Shares
12 transactions
Others Institutions Holding ITCI
# of Institutions
417Shares Held
88.5MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.25 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$811 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$657 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$417 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$412 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.1B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...